Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful faithfully but unsuccessfully to develop an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past several shares of mine. My 1st CytoDyn article, “CytoDyn: What In order to Do When It’s Too Good to be able to Be True?”, set out the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such a highly promotional picture in the Uptick Newswire interview which I came away with an inadequate viewpoint of the company.

Irony of irony, my bad impression of the business enterprise has grown steadily, yet the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the technology and also connected intellectual property from Progenics to CytoDyn, as well as approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) plus the first new drug application endorsement ($five million), as well as royalty payments of 5 % of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to get a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many therapies and numerous indications, it’s this individual therapies and a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an energetic organization with diverse interests albeit focused on leronlimab, multiple illness sorts, multiple presentations in addition to multiple publications.

Could all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself with the very beginning of my interest in this particular organization. Judging by way of the multiples of thousands of several responses on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or some might say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *